Smith Assortment | Archive Photographs | Getty Pictures
Weight problems drug developer Metsera stated on Friday that it had accepted Pfizer‘s $10 billion acquisition provide, in what might spell the tip of a bidding conflict between the New York-based pharma big and rival Novo Nordisk that erupted during the last week.
Pfizer had appeared to have locked up this acquisition in September earlier than Novo jumped in final week, sparking a strategic struggle for a coveted asset within the rising weight reduction market. Pfizer is making an attempt to realize a toehold in that market to beat previous in-house stumbles in creating weight-loss medicine.
Pfizer stated it could pay $86.25 per share in money, a premium of three.69% to Metsera’s Friday shut. The provide contains $65.60 per share in money and a contingent worth proper (CVR) entitling holders to further funds of as much as $20.65 per share in money.
Novo needs to get better its once-commanding place in weight problems medicine it misplaced to Eli Lilly It’s unclear if they may make one other provide, or if Metsera would entertain one other bid. The corporate, in its Friday assertion, stated Novo’s proposal presents “unacceptably excessive authorized and regulatory dangers” in comparison with the proposed merger with Pfizer.
Metsera’s board really useful its shareholders approve the amended Pfizer provide. In an announcement, Pfizer stated it was happy to have reached an settlement with Metsera.
The biotech firm at present loses cash and analysts anticipate additional losses whereas its medicine are nonetheless in improvement.
The bidding conflict between Pfizer and Novo took the value from Pfizer’s $7.3 billion provide in September to the present worth. It had escalated right into a authorized and strategic standoff, with Novo searching for to wrest Metsera from Pfizer’s grip via an advanced deal construction that has drawn scrutiny from regulators.
Metsera’s experimental weight problems medicine MET-097i – a GLP-1 injectable – and MET-233i, which mimics the pancreatic hormone amylin, are projected to achieve $5 billion in mixed peak gross sales, in response to Leerink Companions analyst David Risinger.
